In the News / Politics

Suffering from migraines? Eptinezumab-jjmr (Vyepti™) might be the answer

By: Alisha Kuriakose, PharmD Candidate c/o 2022 Every ten seconds, someone in the United States (U.S.) goes to the emergency…

6 years ago

Combating the neglected consequences of the opioid crisis

By: Mah Noor, PharmD Candidate c/o 2021 Although the opioid crisis began in the late 1990s, there has been a…

6 years ago

COVID-19: The 2019 novel coronavirus

By: Darien Lee, PharmD Candidate c/o 2021            Wuhan, the most populous city in Central China, has a population of…

6 years ago

FDA approves romosozumab (Evenity®) for the treatment of postmenopausal osteoporosis

By: Michael Lim, PharmD Candidate c/o 2020            Osteoporosis is a bone disease affecting nearly ten million people in the…

7 years ago

The rising cost of insulin

By: Daniela Farzadfar, PharmD Candidate c/o 2020            Over 30 million Americans are currently living with diabetes. According to the…

7 years ago

Food and Drug Administration approves lofexidine (LucemyraTM): the first non-addictive opioid withdrawal therapy in the United States

By: Evanthia Siozios, PharmD Candidate c/o 2020            Anxiety, nausea, muscle pain, insomnia are some of the most common withdrawal…

7 years ago

The “Netflix” approach to hepatitis C drugs

By: Michael Lim, PharmD Candidate c/o 2020            In a February 2019 Senate Finance Committee hearing, executives from major pharmaceutical…

7 years ago

Bridging medicine and technology: FDA approves first digital inhaler

By: Michael Lim, PharmD Candidate c/o 2020            As modern technology continues to grow ever more complex and powerful, it…

7 years ago

United States Department of Health and Human Services (HHS) recommends co-prescribing naloxone (Narcan®) with opioids in patients with high opioid overdose risk

By: Michael Lim, PharmD Candidate c/o 2020            In 2017, 70,237 overdose deaths occurred in the United States. Of those…

7 years ago

Esketamine (Spravato™): a new treatment option for depression

By: Sylvia Hong (PharmD Candidate c/o 2021), Muaz Sadeia (PharmD Candidate c/o 2021)            On March 5, 2019, Janssen Pharmaceuticals…

7 years ago